The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Open accessThe DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index; 120 of the 173 sources its claims cite were checked for support.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease in the world. The disease progresses from steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The modern concept of "multiple parallel hits" interprets disease progression as the result of the synergistic action of lipotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, proinflammatory signals, and gut-liver axis dysfunction. Against the background of the limited translation of preclinical data from animal models due to interspecies differences, the importance of human-oriented in vitro platforms compatible with controlled design and high-throughput screening is increasing. The current review analyzes MASLD models based on the HepG2 cell line, systematizing steatosis induction protocols, evaluating the metabolic characteristics and limitations of this cell, and comparing 2D monocultures, 3D systems, and co-cultures. HepG2 has been shown to demonstrate a predictable steatogenic response to free fatty acids (FFAs) and is convenient for reproducing early stages of pathogenesis and primary pharmacological selection of compounds. At the same time, key limitations of the model are highlighted, namely tumor origin, glycolytic shift (Warburg effect), reduced β-oxidation, impaired very-low-density lipoprotein (VLDL) assembly and secretion, and sharply reduced cytochrome P450 (CYP450) activity, as well as limited reproducibility of fructose-induced de novo lipogenesis (DNL). Comparative analysis demonstrates an increase in physiological relevance with the transition from 2D to 3D and multicomponent co-cultures, accompanied by increased complexity and cost, but allowing for the modeling of inflammation and fibrogenesis. The review justifies approaches to selecting the appropriate platform based on the specific research task.
Overview
CoChat Summary
## TL;DR
This narrative review argues that HepG2 is a useful but incomplete human in vitro model for MASLD, especially for early hepatocyte-centric events like steatosis, lipotoxicity, ER stress, oxidative stress, and mitochondrial dysfunction. It concludes that model choice should match the research question, with 2D HepG2 best for rapid screening and 3D/co-culture systems better for inflammation, fibrogenesis, and higher physiological relevance.
## Key findings
- HepG2 shows a predictable steatogenic response to free fatty acids and is widely used for MASLD/NAFLD modeling; the review says 2D monocultures are the most accessible tool for early cell damage and can reproduce lipid accumulation, lipotoxicity, ER stress, oxidative stress, and mitochondrial dysfunction.
- For 2D HepG2 models, the review identifies OA:PA in a 2:1 ratio at 0.5–1.0 mM for 24 h as the preferred setup for screening anti-steatotic effects, because it balances steatogenesis and viability.
- In one cited study, a 2:1 OA/PA ratio at 2 mM induced significant lipid accumulation with minimal toxicity, while palmitate alone caused pronounced cytotoxic and apoptotic responses; another cited triculture model using FFAs + glucose + insulin + LPS + TGF-β + BSA reproduced steatosis, oxidative stress, inflammation, and fibrogenesis.
- The review states that physiological relevance increases from 2D monocultures to 3D models to multicomponent co-cultures, but complexity and cost also rise; 3D organ-on-a-chip platforms are highlighted for simultaneously assessing therapeutic efficacy and toxicity.
## Methods
- Narrative review of MASLD models based on the HepG2 cell line.
- The paper synthesizes published experimental protocols and compares modeling approaches across 2D monocultures, 3D systems, and co-cultures/tricultures.
- Main analysis focuses on steatosis induction conditions, metabolic characteristics and limitations of HepG2, and the physiological relevance of different model formats.
## Limitations
- Stated in the paper: HepG2 has tumor origin, a glycolytic shift (Warburg effect), reduced β-oxidation, impaired VLDL assembly/secretion, sharply reduced CYP450 activity, and limited reproducibility for fructose-induced de novo lipogenesis.
- Stated in the paper: 2D HepG2 monocultures lack non-parenchymal liver cells and non-physiological geometry, while 3D models are harder to standardize and can limit access for post-experimental analysis.
- Evident from the text: this is a narrative review rather than a new experimental study, so its conclusions depend on heterogeneous published studies with differing FFA compositions, exposure times, and readouts.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
65 Valid · 4 Not valid · 11 Not checked · 40 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The major human isoenzymes of drug metabolism (CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2) lack direct orthologs in mice.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 2. Advantages of MASLD Models on Cell Lines Compared to Animals > 2.1. Species-Specific Differences in Metabolism
What the sources say
- Disputedcites [53] Hammer, 2021, Cross-Species Analysis of Hepatic Cytochrome P450 and Transport Protein Expression, Arch. Toxicol. sourceExperimental — accuracy not yet measured
Results, Table 1 is titled “Selected orthologous CYP proteins in human, rat and mouse” and lists mouse counterparts for CYP1A2, CYP2D6, CYP2C9, and CYP2C19. Its mouse entry for CYP3A4 is blank, so the paper does not support the claim that all five lack direct mouse orthologs. Page numbers were not supplied in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Could not verifycites [54] Martignoni, 2006, Comparison of Mouse and Rat Cytochrome P450-Mediated Metabolism in Liver and Intestine, Drug Metab. Dispos. Biol. Fate Chem. sourceExperimental — accuracy not yet measured
Our copy of Martignoni et al. (2006) never states that the major human drug-metabolizing isoenzymes lack direct orthologs in mouse. The closest passages only describe species/organ differences in P450 profile — the Discussion (p. ~1050) notes mouse CYP3A11/13/25/41 versus human CYP3A4/5, and the results section on rat intestinal metabolism (p. ~1053) says 'species differences in liver/intestine ratios of enzyme activities make interspecies extrapolation hazardous' — neither addresses orthology. CYP2C9 and CYP1A2 do not appear anywhere in our copy; CYP2D6, CYP2C19 and CYP1A1 are mentioned only as low-expression isoforms in the human intestine (citing Doherty and Charman, 2002), and mouse/rat CYP2D and CYP2C contributions are discussed for specific substrates (Wan et al., 1997; Perloff et al., 2000). Searched: 'lack direct orthologs', 'ortholog of human CYP2D6/CYP2C9 in mouse', 'interspecies extrapolation / species differences CYP isoform'; the claim's point is not covered, so it can be neither confirmed nor contradicted from this source. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The range of 0.1 to 2.0 mM for the combination of FAs is the standard range for modeling MASLD in 2D HepG2 monoculture [93,100,125,126,127,128].”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 3. Human Liver Cell Lines for Modeling NAFLD > 3.3. Analysis of MASLD Models in HepG2 Cells
What the sources say
- Not checked yetcites [93] Cui, 2010, Quantification and Mechanisms of Oleic Acid-Induced Steatosis in HepG2 Cells, Am. J. Transl. Res.
- Not matchedcites [100] 2015, In Vitro Treatment of HepG2 Cells with Saturated Fatty Acids Reproduces Mitochondrial Dysfunction Found in Nonalcoholic Steatohepatitis, Dis. Model. Mech.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [125] Arruda, V.M., Azevedo, G.T., Granato, M.J.M.G., Matos, A.C.P., Araújo, T.G., and Guerra, J.F.d.C. (2024). Oxidative Stress and Annexin A2 Differential Expression in Free Fatty Acids-Induced Non-Alcoholic Fatty Liver Disease in HepG2 Cells. Int. J. Mol. Sci., 25. sourceExperimental — accuracy not yet measured
The Introduction says there is little consensus on experimental standardization, contrary to calling 0.1–2.0 mM a standard range. The Discussion instead describes concentrations of 0.3–3 mM in most in vitro studies. Although this paper uses combined fatty acids at 1 and 2 mM in HepG2 cells (Materials and Methods, §4.3), it does not establish the claimed range as standard. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [126] Donato, 2007, A Human Hepatocellular in Vitro Model to Investigate Steatosis, Chem. Biol. Interact. source
- Not checked — no full text of the sourcecites [127] Torabi, 2025, Investigating the Process of Apoptosis in HepG2 Cells Treated with Palmitate, Oleate, and Palmitate/Oleate Combination, Arab J. Gastroenterol. source
- Not checked — no full text of the sourcecites [128] Bao, Q., Zhang, X., Chen, Y., Wang, T., and Siqin, B. (2024). In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease. J. Vis. Exp. JoVE. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Along with this, the HepG2 cell line shows functional weakening of mitochondrial β-oxidation of fatty acids.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 3. Human Liver Cell Lines for Modeling NAFLD > 3.2. Metabolic Profile, Advantages, and Limitations of the HepG2 Cell Line for Modeling MASLD
What the sources say
- Not matchedcites [100] 2015, In Vitro Treatment of HepG2 Cells with Saturated Fatty Acids Reproduces Mitochondrial Dysfunction Found in Nonalcoholic Steatohepatitis, Dis. Model. Mech.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [101] Suzuki, 2023, CLPX Regulates Mitochondrial Fatty Acid β-Oxidation in Liver Cells, J. Biol. Chem. sourceExperimental — accuracy not yet measured
The Results section, “Knockout of CLPX induces β-oxidation in HepG2 cells” (page unavailable), reports that untreated HepG2 cells with CLPX had lower mitochondrial β-oxidation activity than CLPX-knockout HepG2 cells. This supports reduced activity under that specific comparison, but not a general claim that the HepG2 cell line has functionally weakened β-oxidation. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, in vitro models express human apolipoproteins, lipoprotein receptors, and lipid transport proteins [43,44,45,46], providing a metabolically relevant context for studying lipid accumulation pathways relevant to MASLD.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 2. Advantages of MASLD Models on Cell Lines Compared to Animals > 2.1. Species-Specific Differences in Metabolism
What the sources say
- Partly supportedcites [43] Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., and Stangl, H. (2025). Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems. Biomolecules, 15. sourceExperimental — accuracy not yet measured
Section 4.5 reports that liver organoids express several apolipoproteins and have lipoprotein receptors, and proposes using them to study lipid-droplet formation and MAFLD progression. The paper discusses lipid transport proteins, but the cited passages do not establish their expression in these in vitro models; that part of the attributed claim remains unsupported. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [44] Ramli, 2020, Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease, Gastroenterology source
- Not matchedcites [45] Moon, 2016, Complex Effects of Inhibiting Hepatic Apolipoprotein B100 Synthesis in Humans, Sci. Transl. Med.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [46] Pollard, 2016, High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation, Biochemistry sourceExperimental — accuracy not yet measured
The Materials and Methods section ('Cell Culture and Purification of Nascent HDL'; page unavailable) describes an in vitro model using HEK293 cells expressing the lipid transporter ABCA1, incubated with human apoA-I. The paper does not show those cells expressing apolipoproteins or lipoprotein receptors, and it studies HDL formation rather than lipid accumulation pathways in MASLD. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Against the background of the limited translation of preclinical data from animal models due to interspecies differences, the importance of human-oriented in vitro platforms compatible with controlled design and high-throughput screening is increasing.”
- Also stated in: § 1. Introduction · plain
“Animal models have provided valuable insights into the disease, but interspecies differences in liver metabolism, genetics, and disease progression limit the transferability of results [26,27].”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > Abstract
What the sources say
- Supportedcites [26] Soret, P.-A., Magusto, J., Housset, C., and Gautheron, J. (2021). In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J. Clin. Med., 10. source
The Conclusions (page unavailable) describe disappointing translation of preclinical findings to humans, identify interspecies differences as a challenge, and discuss advances in in vitro models. Section 3.3 (page unavailable) says organoids can support high-throughput screening and that chip models are more reproducible because of standardized protocols, supporting the claim about human-oriented platforms and controlled design. (LLM, conf=0.88)
- Partly supportedcites [27] Wang, S.-X., Yan, J.-S., and Chan, Y.-S. (2022). Advancements in MAFLD Modeling with Human Cell and Organoid Models. Int. J. Mol. Sci., 23. sourceExperimental — accuracy not yet measured
Section 1.4 says species-specific differences may hinder translation from animal MAFLD models and calls human in vitro models critical. The Concluding Remarks identify high-throughput drug screening as an application, while Section 4.1 describes precise control of microfluidic models but says their low throughput makes high-throughput screening challenging. The claim therefore overgeneralizes the combination of controlled design and high-throughput compatibility. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
34 more claims · 17 with their cited sources checked
Create a free account to see all 120 claims and to verify the 13 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 14
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The Principles of Humane Experimental Technique
(1960) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1960.tb73127.x · Cited by 4,912
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Triglyceride Metabolism in the Liver
Alves‐Bezerra, M., & Cohen, D. E. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170012 · Cited by 1,016
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Global Incidence and Prevalence of Nonalcoholic Fatty Liver Disease
Teng, M. L., Ng, C. H., Huang, D. Q., Chan, K. E., Tan, D. J., Lim, W. H., Yang, J. D., Tan, E., & Muthiah, M. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0365 · Cited by 727
Gerets, H. H. J., Tilmant, K., Gerin, B., Chanteux, H., Depelchin, B. O., Dhalluin, S., & Atienzar, F. A. (2012) · Cell Biology and Toxicology · doi:10.1007/s10565-011-9208-4 · Cited by 698
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
The 3Rs and Humane Experimental Technique: Implementing Change
Hubrecht, R. C., & Carter, E. (2019) · Animals · doi:10.3390/ani9100754 · Cited by 613
A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes
Stefan, N., & Cusi, K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00003-1 · Cited by 593
A Human Hepatocellular in Vitro Model to Investigate Steatosis
Gómez-Lechón, M. J., Donato, M. T., Martínez-Romero, A., Jiménez, N., Castell, J. V., & O’Connor, J.-E. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.004 · Cited by 576
Global Epidemiology of Chronic Liver Disease
Cheemerla, S., & Balakrishnan, M. (2021) · Clinical Liver Disease · doi:10.1002/cld.1061 · Cited by 571
Westerink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.05.014 · Cited by 544
Russell and Burch's 3Rs then and now: the need for clarity in definition and purpose.
Tannenbaum, J., & Bennett, B. T. (2015) · PubMed · Cited by 535
DeWaal, D., Nogueira, V., Terry, A. R., Patra, K. C., Jeon, S.-M., Guzman, G., Au, J., Long, C. P., Antoniewicz, M. R., & Hay, N. (2018) · Nature Communications · doi:10.1038/s41467-017-02733-4 · Cited by 525
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests
Szymański, P., Markowicz, M., & Mikiciuk-Olasik, E. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms13010427 · Cited by 454
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Tilg, H., Adolph, T. E., & Moschen, A. R. (2021) · Hepatology · doi:10.1002/hep.31518 · Cited by 426
Rodríguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., Castell, J. V., & Gómez-Lechón, M.-J. (2002) · Xenobiotica · doi:10.1080/00498250210128675 · Cited by 420
Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.03.006 · Cited by 416
The Curious Case of the HepG2 Cell Line: 40 Years of Expertise
Arzumanian, V. A., Kiseleva, O. I., & Poverennaya, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313135 · Cited by 387
A feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386
FDA Modernization Act 2.0 allows for alternatives to animal testing
Han, J. J. (2023) · Artificial Organs · doi:10.1111/aor.14503 · Cited by 381
Preclinical models of non-alcoholic fatty liver disease
Santhekadur, P. K., Kumar, D. P., & Sanyal, A. J. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.031 · Cited by 380
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes
Ly, L. D., Xu, S., Choi, S.-K., Ha, C.-M., Thoudam, T., Cha, S.-K., Wiederkehr, A., Wollheim, C. B., Lee, I.-K., & Park, K.-S. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.157 · Cited by 378
Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances
Lau, J. K. C., Zhang, X., & Yu, J. (2017) · The Journal of Pathology · doi:10.1002/path.4829 · Cited by 373
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical
Hagström, H., Vessby, J., Ekstedt, M., & Shang, Y. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.026 · Cited by 372
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0239 · Cited by 357
Guo, L., Dial, S., Shi, L., Branham, W., Liu, J., Fang, J.-L., Green, B., Deng, H., Kaput, J., & Ning, B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035873 · Cited by 348
Simard, J. R., Zunszain, P. A., Hamilton, J. A., & Curry, S. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.028 · Cited by 344
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease
Ramli, M. N. B., Lim, Y. S., Koe, C. T., Demircioglu, D., Tng, W., Gonzales, K. A. U., Tan, C. P., Szczerbinska, I., Liang, H., Soe, E. L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.010 · Cited by 278
From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
Rinella, M. E., & Sookoian, S. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100485 · Cited by 250
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Dharmalingam, M., & Yamasandhi, P. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_585_17 · Cited by 239
Westerink, W. M. A., & Schoonen, W. G. E. J. (2007) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.06.017 · Cited by 226
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r001610 · Cited by 220
Yin, W., Carballo-Jane, E., McLaren, D. G., Mendoza, V. H., Gagen, K., Geoghagen, N. S., McNamara, L. A., Gorski, J. N., Eiermann, G. J., Petrov, A., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m019927 · Cited by 218
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433857 · Cited by 211
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity, Tacke, F., Horn, P., Wong, V. W.-S., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06196-3 · Cited by 208
Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells.
(2010) · PubMed Central · Cited by 181
Cell Culture Models of Fatty Acid Overload: Problems and Solutions
Alsabeeh, N., Chausse, B., Kakimoto, P. A., Kowaltowski, A. J., & Shirihai, O. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.11.006 · Cited by 167
Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells
Ramirez, T., Strigun, A., Verlohner, A., Huener, H.-A., Peter, E., Herold, M., Bordag, N., Mellert, W., Walk, T., Spitzer, M., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2079-6 · Cited by 164
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., & Persico, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183415 · Cited by 164
Egnatchik, R. A., Leamy, A. K., Noguchi, Y., Shiota, M., & Young, J. D. (2014) · Metabolism · doi:10.1016/j.metabol.2013.10.009 · Cited by 161
The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death
Kamalian, L., Chadwick, A. E., Bayliss, M., French, N. S., Monshouwer, M., Snoeys, J., & Park, B. K. (2015) · Toxicology in Vitro · doi:10.1016/j.tiv.2015.02.011 · Cited by 160
Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Henderson, G. C. (2021) · Nutrients · doi:10.3390/nu13082590 · Cited by 152
Polyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31824587e0 · Cited by 152
Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis
Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lindén, D., & Romeo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071629 · Cited by 152
Gordon, S. M., Li, H., Zhu, X., Shah, A. S., Lu, L. J., & Davidson, W. S. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00213 · Cited by 141
Trajkovska, K. T., & Topuzovska, S. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7608 · Cited by 141
Alnahdi, A., John, A., & Raza, H. (2019) · Nutrients · doi:10.3390/nu11091979 · Cited by 134
Meex, S. J. R., Andreo, U., Sparks, J. D., & Fisher, E. A. (2011) · Journal of Lipid Research · doi:10.1194/jlr.d008888 · Cited by 129
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Precision-cut liver slices: a versatile tool to advance liver research
Palma, E., Doornebal, E. J., & Chokshi, S. (2019) · Hepatology International · doi:10.1007/s12072-018-9913-7 · Cited by 125
Eynaudi, A., Díaz-Castro, F., Bórquez, J. C., Bravo-Sagua, R., Parra, V., & Troncoso, R. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.775382 · Cited by 125
In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal
Soret, P.-A., Magusto, J., Housset, C., & Gautheron, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010036 · Cited by 121
Human in vitro models of nonalcoholic fatty liver disease
Müller, F. A., & Sturla, S. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.03.001 · Cited by 118
3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells
Takahashi, Y., Hori, Y., Yamamoto, T., Urashima, T., Ohara, Y., & Tanaka, H. (2015) · Bioscience Reports · doi:10.1042/bsr20150034 · Cited by 118
Yang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2020) · doi:10.1101/2020.06.10.141606 · Cited by 110
Hoekstra, M., Li, Z., Kruijt, J. K., Eck, M. V., Berkel, T. J. C. V., & Kuiper, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.11.004 · Cited by 108
Li, X., Ma, J., & Wang, J. (2015) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2015.06.018 · Cited by 105
Cross-species analysis of hepatic cytochrome P450 and transport protein expression
Hammer, H., Schmidt, F., Marx-Stoelting, P., Pötz, O., & Braeuning, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02939-4 · Cited by 104
Xuan, J., Chen, S., Ning, B., Tolleson, W. H., & Guo, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.10.009 · Cited by 103
Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load
Gambino, R., Bugianesi, E., Rosso, C., Mezzabotta, L., Pinach, S., Alemanno, N., Saba, F., & Cassader, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040479 · Cited by 101
COMPARISON OF MOUSE AND RAT CYTOCHROME P450-MEDIATED METABOLISM IN LIVER AND INTESTINE
Martignoni, M., Groothuis, G., & de Kanter, R. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009035 · Cited by 101
Yang, J., Hirai, Y., Iida, K., Ito, S., Trumm, M., Terada, S., Sakai, R., Tsuchiya, T., Tabata, O., & Kamei, K.-I. (2023) · Communications Biology · doi:10.1038/s42003-023-04710-8 · Cited by 98
Lipotoxicity in HepG2 cells triggered by free fatty acids.
(2011) · PubMed Central · Cited by 94
Alaaeldin, R., Abdel-Rahman, I. A. M., Hassan, H. A., Youssef, N., Allam, A. E., Abdelwahab, S. F., Zhao, Q.-L., & Fathy, M. (2021) · Molecules · doi:10.3390/molecules26247629 · Cited by 92
Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Imajo, K., Yoneda, M., Kessoku, T., Ogawa, Y., Maeda, S., Sumida, Y., Hyogo, H., Eguchi, Y., Wada, K., & Nakajima, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121833 · Cited by 89
Peroxisomal fatty acid β-oxidation in HepG2 cells
Watkins, P. A., Ferrell, E. V., Pedersen, J. I., & Hoefler, G. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90419-j · Cited by 86
Tauil, R. B., Golono, P. T., de Lima, E. P., Goulart, R. D. Á., Guiguer, É. L., Bechara, M. D., Nicolau, C. C. T., Yanaguizawa, J. L., Fiorini, A. M. R., Méndez‐Sánchez, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101354 · Cited by 85
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
García-Ruiz, I., Solís-Muñoz, P., Fernández-Moreira, D., Muñoz-Yagüe, T., & Solís-Herruzo, J. A. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.018234 · Cited by 83
Precision-cut human liver slice cultures as an immunological platform
Wu, X., Roberto, J. B., Knupp, A., Kenerson, H. L., Truong, C. D., Yuen, S. Y., Brempelis, K. J., Tuefferd, M., Chen, A., Horton, H., et al. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.01.012 · Cited by 81
PNPLA3 expression and its impact on the liver: current perspectives
Bruschi, F. V., Tardelli, M., Claudel, T., & Trauner, M. (2017) · Hepatic Medicine: Evidence and Research · doi:10.2147/hmer.s125718 · Cited by 81
Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives
Voloshin, N., Tyurin-Kuzmin, P., Karagyaur, M., Akopyan, Z., & Kulebyakin, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612716 · Cited by 77
Haplotype-resolved and integrated genome analysis of the cancer cell line HepG2
Zhou, B., Ho, S. S., Greer, S. U., Spies, N., Bell, J. M., Zhang, X., Zhu, X., Arthur, J. G., Byeon, S., Pattni, R., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz169 · Cited by 72
Štampar, M., Breznik, B., Filipič, M., & Žegura, B. (2020) · Cells · doi:10.3390/cells9122557 · Cited by 70
Leichman, J. G., Aguilar, D., King, T. M., Vlada, A., Reyes, M., & Taegtmeyer, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.2.336 · Cited by 64
Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD
Termite, F., Archilei, S., D’Ambrosio, F., Petrucci, L., Viceconti, N., Iaccarino, R., Liguori, A., Gasbarrini, A., & Miele, L. (2025) · Antioxidants · doi:10.3390/antiox14010056 · Cited by 63
Ceja-Galicia, Z. A., Cespedes-Acuña, C. L. A., & El-Hafidi, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020788 · Cited by 61
Ischemia-modified albumin: Crosstalk between fatty acid and cobalt binding
Coverdale, J. P. C., Katundu, K. G. H., Sobczak, A. I. S., Arya, S., Blindauer, C. A., & Stewart, A. J. (2018) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2018.07.014 · Cited by 60
Hirahatake, K. M., Meissen, J. K., Fiehn, O., & Adams, S. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026583 · Cited by 55
Unbound free fatty acid profiles in human plasma and the unexpected absence of unbound palmitoleate
Huber, A. H., & Kleinfeld, A. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074260 · Cited by 53
Application of In Vitro Metabolism Activation in High-Throughput Screening
Ooka, M., Lynch, C., & Xia, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218182 · Cited by 49
Amorim, R., Simões, I. C. M., Teixeira, J., Cagide, F., Potes, Y., Soares, P., Carvalho, A., Tavares, L. C., Benfeito, S., Pereira, S. P., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102400 · Cited by 48
Inhibitory Effect of Gardenoside on Free Fatty Acid-Induced Steatosis in HepG2 Hepatocytes
Liang, H., Zhang, L., Wang, H., Tang, J., Yang, J., Chuncheng, W., & Chen, S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161126058 · Cited by 48
Su, R. C., Lad, A. C., Breidenbach, J. D., Blomquist, T. M., Gunning, W. T., Dube, P. R., Kleinhenz, A. L., Malhotra, D. K., Haller, S. T., & Kennedy, D. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225604 · Cited by 47
ALKHATATBEH, M. J., LINCZ, L. F., & THORNE, R. F. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3069 · Cited by 44
Chen, S., Wu, Q., Li, X., Li, D., Mei, N., Ning, B., Puig, M., Ren, Z., Tolleson, W. H., & Guo, L. (2021) · Journal of Environmental Science and Health, Part C · doi:10.1080/26896583.2021.1880242 · Cited by 44
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Kosmalski, M., Śliwińska, A., & Drzewoski, J. (2023) · Biomedicines · doi:10.3390/biomedicines11041097 · Cited by 42
Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy
Leith, D., Lin, Y. Y., & Brennan, P. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.2 · Cited by 41
Mechanisms of tolvaptan-induced toxicity in HepG2 cells
Wu, Y., Beland, F. A., Chen, S., Liu, F., Guo, L., & Fang, J.-L. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.015 · Cited by 41
Minniti, M. E., Pedrelli, M., Vedin, L., Delbès, A., Denis, R. G. P., Öörni, K., Sala, C., Pirazzini, C., Thiagarajan, D., Nurmi, H. J., et al. (2020) · Hepatology · doi:10.1002/hep.31052 · Cited by 38
Non-alcoholic fatty liver disease: pathogenesis and models
Zhong, H. (2024) · American Journal of Translational Research · doi:10.62347/kmsa5983 · Cited by 37
Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity
Ruoß, M., Damm, G., Vosough, M., Ehret, L., Grom-Baumgarten, C., Petkov, M., Naddalin, S., Ladurner, R., Seehofer, D., Nussler, A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020347 · Cited by 37
Huggett, Z. J., Smith, A., De Vivo, N., Gomez, D., Jethwa, P., Brameld, J. M., Bennett, A., & Salter, A. M. (2022) · Nutrients · doi:10.3390/nu15010040 · Cited by 37
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
Reyes‐Soffer, G., Moon, B. C., Hernández‐Ono, A., Dionizovik-Dimanovski, M., Jimenez, J., Obunike, J. C., Thomas, T. A., Ngai, C. I., Fontanez, N., Donovan, D. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2195 · Cited by 36
Castillo, H. B., Shuster, S. O., Tarekegn, L. H., & Davis, C. M. (2024) · Chemical Communications · doi:10.1039/d3cc04829b · Cited by 32
A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
Chitale, S., Wu, W., Mukherjee, A., Lannon, H., Suresh, P., Nag, I., Ambrosi, C. M., Gertner, R. S., Melo, H., Powers, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43333-9 · Cited by 29
Thusyanthan, J., Wickramaratne, N. S., Senathilake, K. S., Rajagopalan, U., Tennekoon, K. H., Thabrew, I., & Samarakoon, S. R. (2022) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2022/6407688 · Cited by 29
Rodent model of metabolic dysfunction‐associated fatty liver disease: a systematic review
Cui, X., Li, H., Li, L., Xie, C., Gao, J., Chen, Y., Zhang, H., Hao, W., Fu, J., & Guo, H. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16749 · Cited by 27
Roy, S., Parveen, M., Bala, A., & Sur, D. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00661 · Cited by 26
Aristizabal, J., González-Zapata, L., Estrada-Restrepo, A., Monsalve-Alvarez, J., Restrepo-Mesa, S., & Gaitán, D. (2018) · Nutrients · doi:10.3390/nu10010031 · Cited by 24
Arabi, Y. M., Tamimi, W., Jones, G., Jawdat, D., Tamim, H., Al-Dorzi, H. M., Sadat, M., Afesh, L., Sakhija, M., & Al-Dawood, A. (2019) · Nutrients · doi:10.3390/nu11020384 · Cited by 24
Ericson, E., Bergenholm, L., Andréasson, A., Dix, C. I., Knöchel, J., Hansson, S., Lee, R. G., Schumi, J., Antonsson, M., Fjellström, O., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2032 · Cited by 23
Pipiya, V. V., Gilazieva, Z. E., Issa, S. S., Rizvanov, A. A., & Solovyeva, V. V. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00237 · Cited by 23
Huang, L., Zeng, X., Li, B., Wang, C., Zhou, M., Lang, H., Yi, L., & Mi, M. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00612-w · Cited by 23
Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review)
Ma, Q., Liu, K., Chang, C., Wang, L., Shen, Z.-Y., Li, J., Adu, M., Lin, Q., Huang, H., Wu, X., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5668 · Cited by 23
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
García-Ruiz, I., Solís-Muñoz, P., Gómez-Izquierdo, É., Muñoz-Yagüe, M. T., Valverde, Á. M., & Solís-Herruzo, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.342709 · Cited by 22
Chen, H., Wu, Q., Peng, L., Cao, T., Deng, M.-L., Liu, Y.-W., Huang, J., Hu, Y., Fu, N., Zhou, K.-B., et al. (2021) · Journal of Nanomaterials · doi:10.1155/2021/5164100 · Cited by 22
Amorim, R., Simões, I., Veloso, C., Carvalho, A., Simões, R., Pereira, F., Thiel, T., Normann, A., Morais, C., Jurado, A., et al. (2021) · Nutrients · doi:10.3390/nu13051723 · Cited by 21
Maseko, T., Elkalaf, M., Peterová, E., Lotková, H., Staňková, P., Melek, J., Dušek, J., Žádníková, P., Čížková, D., Bezrouk, A., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5342 · Cited by 21
Zhao, Y. M., Zhao, W., Ma, J., Toshiyoshi, M., & Zhao, Y. (2023) · Medicine · doi:10.1097/md.0000000000033110 · Cited by 21
Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., & Elisia, I. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234300 · Cited by 21
Swapna Sasi, U. S., Sindhu, G., & Raghu, K. G. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104952 · Cited by 19
Oleic acid-induced steatosis model establishment in LMH cells and its effect on lipid metabolism
Song, H., Yang, R., Zhang, J., Sun, P., Xing, X., Wang, L., Sairijima, T., Hu, Y., Liu, Y., Cheng, H., et al. (2023) · Poultry Science · doi:10.1016/j.psj.2022.102297 · Cited by 19
Pollard, R. D., Fulp, B., Sorci-Thomas, M. G., & Thomas, M. J. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00347 · Cited by 19
Nie, Y.-F., Meng, W., Liu, D., Yang, Z., Wang, W., Ren, H., Mao, K., Lan, W., Li, C., Wang, Z., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00945-1 · Cited by 18
Chiang, T.-S., Yang, K.-C., Chiou, L.-L., Huang, G.-T., & Lee, H.-S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094885 · Cited by 17
Dave, T., Tilles, A. W., & Vemula, M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217741077 · Cited by 17
Zebularine upregulates expression of CYP genes through inhibition of DNMT1 and PKR in HepG2 cells
Nakamura, K., Aizawa, K., Aung, K. H., Yamauchi, J., & Tanoue, A. (2017) · Scientific Reports · doi:10.1038/srep41093 · Cited by 16
Negoro, R., Tasaka, M., Deguchi, S., Takayama, K., & Fujita, T. (2022) · Cells · doi:10.3390/cells11101677 · Cited by 16
Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases
Xiang, H., Wu, Z., Wang, J., & Wu, T. (2021) · Journal of Cancer · doi:10.7150/jca.57951 · Cited by 15
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
Palmitate lipotoxicity is closely associated with the fatty acid-albumin complexes in BV-2 microglia
Yang, Y., Yu, Q., Li, B., Yang, Z., Zhang, S., & Yuan, F. (2023) · PLOS ONE · doi:10.1371/journal.pone.0281189 · Cited by 15
Ex Vivo Tools and Models in MASLD Research
Velliou, R.-I., Giannousi, E., Ralliou, C., Kassi, E., & Chatzigeorgiou, A. (2024) · Cells · doi:10.3390/cells13221827 · Cited by 15
Nutrient environment improves drug metabolic activity in human iPSC-derived hepatocytes and HepG2
Pozo Garcia, V., Çobanoğlu, T. S., Hammer, H. S., Carlota, R., Holm, K., Verfaillie, C., Poetz, O., Jennings, P., & Moco, S. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04139-4 · Cited by 15
Effect of FTY720P on lipid accumulation in HEPG2 cells
Rida, R., & Kreydiyyeh, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-46011-4 · Cited by 14
Elsabaawy, M., Torkey, M., Magdy, M., & Naguib, M. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-03151-9 · Cited by 14
Novel insights into metabolic‐associated steatotic liver disease preclinical models
Montero‐Vallejo, R., Maya‐Miles, D., Ampuero, J., Martín, F., Romero‐Gómez, M., & Gallego‐Durán, R. (2024) · Liver International · doi:10.1111/liv.15830 · Cited by 14
Arruda, V. M., Azevedo, G. T., Granato, M. J. M. G., Matos, A. C. P., Araújo, T. G., & Guerra, J. F. D. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179591 · Cited by 13
Lei, Y., Ma, X., Liu, T., Wang, M., Kang, J., Yang, J. Q., & Mi, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39890 · Cited by 13
Beyazal Polat, H., Beyazal, M., Arpa, M., Kızılkaya, B., Ayaz, T., Gündoğdu, Ö. L., Konur, K., Polat, Z., Beyazal Çeliker, F., & Atasoy, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103513 · Cited by 13
Paolini, E., Longo, M., Meroni, M., Tria, G., Cespiati, A., Lombardi, R., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1101341 · Cited by 11
Drug-Metabolizing Gene Expression Identity: Comparison Across Liver Tissues and Model Cell Lines
Arzumanian, V. A., Timofeeva, E. V., Kiseleva, O. I., & Poverennaya, E. V. (2025) · Biomedicines · doi:10.3390/biomedicines13112722 · Cited by 11
Han, X., Zhang, X., Liu, Z., Fan, H., Guo, C., Wang, H., Gu, Y., & Zhang, T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13564 · Cited by 11
Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems
Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., & Stangl, H. (2025) · Biomolecules · doi:10.3390/biom15070956 · Cited by 11
Huang, Z., Li, L., Dudley, K., Xiao, L., Huang, G., Subramaniam, V. N., Chen, C., Crawford, R., & Xiao, Y. (2025) · BME Frontiers · doi:10.34133/bmef.0181 · Cited by 10
Kim, I., Kyun, M.-L., Jung, H., Kwon, J.-I., Kim, J., Kim, J.-K., Lee, Y. B., Kwon, Y.-I., & Moon, K.-S. (2024) · ACS Omega · doi:10.1021/acsomega.4c02433 · Cited by 10
Liu, J., Zai, X., Tian, X., Li, J., Yan, S., & Wang, T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1543316 · Cited by 10
Youhanna, S., Taebnia, N., Liang, Y., Cheng, N., Wang, Y., Michel, M., & Lauschke, V. M. (2025) · Advanced Biology · doi:10.1002/adbi.202500337 · Cited by 9
Glaesser, D., & Iwig, M. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109888 · Cited by 9
CLPX regulates mitochondrial fatty acid β-oxidation in liver cells
Suzuki, K., Kubota, Y., Kaneko, K., Kamata, C. C., & Furuyama, K. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105210 · Cited by 7
Chen, Y., Yan, X., Wang, T., Deng, H., Deng, X., Xu, F., & Liang, H. (2023) · International Journal of Endocrinology · doi:10.1155/2023/2872408 · Cited by 6
Patulin Alters Insulin Signaling and Metabolic Flexibility in HepG2 and HEK293 Cells
Pillay, Y., Nagiah, S., & Chuturgoon, A. (2023) · Toxins · doi:10.3390/toxins15040244 · Cited by 6
Cui, X., Li, C., He, S., & Li, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-04924-2 · Cited by 6
Effects of Fructose on Features of Steatotic Liver Disease in HepG2 Cells
Howes, M. T., King, J., & Rosengren, R. J. (2025) · Nutrients · doi:10.3390/nu17172762 · Cited by 5
Castelão-Baptista, J. P., Valente, S. A., Canário, S., Oppolzer, D., Barros, A., Venâncio, C., Martins, T., Antunes, L., Sardão, V. A., Rosa, E., et al. (2023) · Nutrients · doi:10.3390/nu15040924 · Cited by 5
Alabdul Razzak, I., Noureddin, M., & Trivedi, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030880 · Cited by 5
Szustak, M., Pichlak, M., Korkus, E., Kamińska, D., Koziołkiewicz, M., Dąbrowski, G., Czaplicki, S., Konopka, I., & Gendaszewska-Darmach, E. (2026) · Scientific Reports · doi:10.1038/s41598-026-37006-y · Cited by 5
Tanaka-yachi, R., Aizawa, K., Shimizu, K., Akutsu, H., & Nakamura, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-25777-z · Cited by 4
Park, S.-M., Choi, M.-S., Kim, S., Jegal, H., Han, H.-Y., Chun, H. S., Kim, S. K., & Oh, J.-H. (2024) · Scientific Reports · doi:10.1038/s41598-024-54634-4 · Cited by 4
Molecular Profile of the HepG2 Tumor Cell Line
Arzumanian, V. A., Pyatnitsky, M., Vakhrushev, I. V., Ptitsyn, K. G., Radko, S. P., Zgoda, V. G., Kiseleva, O. I., & Poverennaya, E. V. (2024) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00239 · Cited by 3
Torabi, S., Mohammadi, Y., Hoseini, M.-S., Rezaei, A., Mohammadi, A., & Bahreini, E. (2025) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2025.09.002 · Cited by 3
Pan, Z., Li, X., Wu, D., Xie, L., Chen, X., & Geng, Z. (2025) · Animals · doi:10.3390/ani15243603 · Cited by 3
Nerusch, J., Schicht, G., Herzog, N., Küpper, J.-H., Seehofer, D., & Damm, G. (2025) · Cells · doi:10.3390/cells14161254 · Cited by 3
Isfahani, M. M., Sepanlou, S. G., Joukar, F., Mansour-Ghanaei, F., & Taheri, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-30226-8 · Cited by 3
Gaser, O. A., Nasr, M. A., Hussein, A. E., Salah, R. A., Saad, S. M., Ehab, S., Aboomar, N. M., Elmehrath, A. O., Salah, A., Chang, Y.-T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-02807-0 · Cited by 2
Elangovan, E. J., Rakuman, R. H., & Vellaichamy, A. (2025) · Cellular and Molecular Biology · doi:10.14715/cmb/2025.71.11.9 · Cited by 2
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-associated Steatotic Liver Disease
Bao, Q., Zhang, X., Chen, Y., Wang, T., & Siqin, B. (2024) · Journal of Visualized Experiments · doi:10.3791/66810 · Cited by 1
Cited by
Котлярова, А. А., & Kotlyarov, S. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104453 · Cited by 1
Self-citationDistinct OA:PA Ratios Generate Discrete Hepatocellular Phenotypes in HepG2 Cells
Jeong, H. Y., Han, Y., Park, J., Noh, H., Moon, E., & Huh, Y. (2026) · Cells · doi:10.3390/cells15191774
Kavak, E., Çetin, D., Konuş, M., & Kıvrak, A. (2026) · ACS Omega · doi:10.1021/acsomega.6c04482
Feguro, K. F., Fauzi, N. M., Husain, K., Mustafa, S. H., & Jasamai, M. (2026) · Molecules · doi:10.3390/molecules31152708
Xiao, Z., Bian, H., & Huang, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154435
Metadata
- Authors
- Kotlyarova, A., Iskrina, A., & Kotlyarov, S.
- Affiliations
- Department of Pharmacy Management and Economics, Ryazan State Medical University, 390026 Ryazan, Russia
- Ryazan State Medical University named after Academician I.P. Pavlov (RU)
- Corresponding author
- Kotlyarov, Stanislav
- Venue
- International journal of molecular sciences
- Publisher
- MDPI AG
- Published
- 2026-04-10
- Volume
- 27
- Issue
- 8
- Pages
- 3399
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13116571
- OpenAlex
- W7153190438
- Cited by
- 10
- References
- 156
- Citations by year
- 2026: 10
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-25-01166)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- HepG2 cells, non-alcoholic fatty liver disease, steatosis, 3D cell culture, co-culture model, free fatty acids, de novo lipogenesis, Warburg effect, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, lipotoxicity, VLDL secretion, cytochrome P450, hepatocellular carcinoma, fibrosis, inflammation, high-throughput screening
- MeSH terms
- Animals, Fatty Liver, Humans, Models, Biological, Hep G2 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.